rs2076295 variants influence nintedanib and pirfenidone outcomes in idiopathic pulmonary fibrosis: a pilot study

rs2076295 variants influence nintedanib and pirfenidone outcomes in idiopathic pulmonary fibrosis: a pilot study

Background: The antifibrotic drugs nintedanib and pirfenidone are used for the treatment of idiopathic pulmonary fibrosis (IPF). We analysed the association of common profibrotic polymorphisms in MUC5B (mucin 5B, rs35705950) and DSP (desmoplakin, rs2076295) on antifibrotic treatment outcomes in IPF....

Full description

Bibliographic Details
Main Authors:	Martina Doubkova, Eva Kriegova, Simona Littnerova, Petra Schneiderova, Martina Sterclova, Vladimir Bartos, Martina Plackova, Monika Zurkova, Radka Bittenglova, Vladimira Lostaková, Lenka Siskova, Pavlina Lisa, Hana Suldova, Michael Doubek, Jana Psikalova, Tomas Snizek, Pavlina Musilova, Martina Vasakova
Format:	Article
Language:	English
Published:	SAGE Publishing 2021-09-01
Series:	Therapeutic Advances in Respiratory Disease
Online Access:	https://doi.org/10.1177/17534666211042529

Similar Items

Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry
by: Monika Zurkova, et al.
Published: (2019-01-01)

Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
by: Manon Belhassen, et al.
Published: (2021-05-01)

Interstitial Score and Concentrations of IL-4Rα, PAR-2, and MMP-7 in Bronchoalveolar Lavage Fluid Could Be Useful Markers for Distinguishing Idiopathic Interstitial Pneumonias
by: Magdalena Bruzova, et al.
Published: (2021-04-01)

Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre
by: E. Bargagli, et al.
Published: (2019-05-01)

Bronchoalveolar lavage cell profiles and proteins concentrations can be used to phenotype extrinsic allergic alveolitis patients
by: Martina Sterclova, et al.
Published: (2019-03-01)

Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study
by: C. C. Moor, et al.
Published: (2020-07-01)

Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis
by: Gareth Hughes, et al.
Published: (2016-09-01)

Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic
by: José M. Serra López-Matencio, et al.
Published: (2021-08-01)

Retrospective Analysis of Medication Utilization and Clinical Outcomes in Patients With Idiopathic Pulmonary Fibrosis Treated With Nintedanib or Pirfenidone
by: Anastasia Y Ipatova, et al.
Published: (2019-03-01)

Pirfenidone vs nintedanib for treatment of idiopathic pulmonary fibrosis in clinical practice: efficacy, tolerability, and adverse effects
by: Amal A.E.-A Sadon, et al.
Published: (2020-01-01)

South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
by: Shaney L. Barratt, et al.
Published: (2018-12-01)

Chemokiny a jejich receptory v patogenezi fibrotizujících plicních procesů
by: Šterclová, Martina
Published: (2009)

Quantitative assessment of specific serum IgGs may verify source of environmental exposure in extrinsic allergic alveolitis (EAA)
by: Martina Sterclova, et al.
Published: (2021-01-01)

Internalisace anti-AßPP protilátek v buňce
by: Doubková, Pavlína
Published: (2009)

Th1/Th2 genový polymorfismus cytokinů u pacientů s idiopatickou plicní fibrózou
by: Vašáková, Martina
Published: (2007)

Effects of Pirfenidone and Nintedanib on Markers of Systemic Oxidative Stress and Inflammation in Patients with Idiopathic Pulmonary Fibrosis: A Preliminary Report
by: Alessandro G. Fois, et al.
Published: (2020-10-01)

Comparison of reversal of rat pulmonary fibrosis of nintedanib, pirfenidone, and human umbilical mesenchymal stem cells from Wharton’s jelly
by: Kuo-An Chu, et al.
Published: (2020-11-01)

Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study
by: Paolo Cameli, et al.
Published: (2020-09-01)

Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis
by: Satoshi Ikeda, et al.
Published: (2019-04-01)

Nintedanib Treatment for Idiopathic Pulmonary Fibrosis Patients Who Have Been Switched from Pirfenidone Therapy: A Retrospective Case Series Study
by: Andrea Vianello, et al.
Published: (2020-02-01)

Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis
by: Mareike Lehmann, et al.
Published: (2018-09-01)

The natural history of progressive fibrosing interstitial lung diseases
by: Martin Kolb, et al.
Published: (2019-03-01)

Zdravá schizofrenie. Vlivy Brechtova epického divadla a zcizujícího efektu v českém moderním herectví
by: Musilová, Martina
Published: (2007)

Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry
by: Colin H. Holtze, et al.
Published: (2020-02-01)

Comparison of the Therapeutic Effect of Pirfenidone, Nintedanib, Human Adipose-derived Mesenchymal Stem Cells and Human Umbilical Mesenchymal Stem Cells from Wharton’s Jelly on Rat Pulmanory Fibrosis
by: Fu-Hsien Kuo, et al.
Published: (2019)

Differentiated Customers’ Loyalty Development in Relation to Different Customer Lifetime Values
by: Hana Loštakova, et al.
Published: (2004-12-01)

Significance of specific IgG against sensitizing antigens in extrinsic allergic alveolitis: Serological methods in EAA
by: M. Sterclova, et al.
Published: (2011-11-01)

Perils with Pirfenidone and “the tuberculosis link”
by: Madhav H Hande, et al.
Published: (2019-01-01)

Nintedanib-Induced Renal Thrombotic Microangiopathy
by: Takeshi Fujita, et al.
Published: (2021-07-01)

Nintedanib in the treatment of idiopathic pulmonary fibrosis
by: Mariano E. Mazzei, et al.
Published: (2015-06-01)

Is nintedanib effective for idiopathic pulmonary fibrosis?
by: Alejandro Jeldres
Published: (2017-06-01)

Focus on Nintedanib in NSCLC and other tumors
by: Anna Manzo, et al.
Published: (2016-12-01)

Nintedanib in idiopathic and secondary pleuroparenchymal fibroelastosis
by: Mouhamad Nasser, et al.
Published: (2021-10-01)

Small Molecule Tyrosine Kinase Inhibitor Nintedanib Reduces Development of Cardiac Allograft Vasculopathy in Murine Aortic Allografts
by: Annika Gocht, et al.
Published: (2018-07-01)

Antifibrotic activities of pirfenidone in animal models
by: L. Pan, et al.
Published: (2011-06-01)

Pirfenidone treatment of idiopathic pulmonary fibrosis
by: Arata Azuma
Published: (2012-04-01)

Application of Pirfenidone anti-fibrosis in ophthalmology
by: Xiao Yang, et al.
Published: (2013-08-01)

Is pirfenidone effective for idiopathic pulmonary fibrosis?
by: Alejandro Jeldres, et al.
Published: (2017-03-01)

Role of pirfenidone in the management of pulmonary fibrosis
by: Meyer KC, et al.
Published: (2017-04-01)

Pirfenidone treatment of idiopathic pulmonary fibrosis
by: Ye Gan, et al.
Published: (2011-02-01)